We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Novel Nanoparticles May Lead to Universal Antiviral Drug

By LabMedica International staff writers
Posted on 02 Jan 2018
A team of molecular virologists has developed a nanoparticle-based broad-spectrum antiviral agent that binds irreversibly to a large range of viruses and causes lethal structural deformations without affecting healthy tissue.

Available antiviral drugs are virus-specific and active against a limited panel of human pathogens. More...
There are broad-spectrum substances that prevent the first step of virus–cell interaction by mimicking heparan sulfate proteoglycans (HSPG), the highly conserved target of viral attachment ligands (VALs). However, the reversible binding mechanism prevents their use as a drug, because, upon dilution, the inhibition is lost. Known VALs are made of closely packed repeating units, but the aforementioned substances are able to bind only a few of them.

To avoid the reversible binding problem, investigators at Ecole Polytechnique Fédérale de Lausanne (Switzerland) designed antiviral nanoparticles with long and flexible linkers that mimicked HSPG. These novel nanoparticles simulated the VAL repeating units and enabled strong and multivalent viral association that eventually led to irreversible viral deformation.

The investigators reported in the December 18, 2017, online edition of the journal Nature Materials that the efficacy of this proposed mechanism was supported by virucidal assays, electron microscopy images, and molecular dynamics simulations. The particles showed no cytotoxicity, and in vitro irreversibly blocked the activity of herpes simplex virus (HSV), human papilloma virus, respiratory syncytial virus (RSV), dengue, and Lentivirus. In addition the particles were active in vitro in human cervicovaginal histocultures infected by HSV-2 and in vivo in mice infected with RSV.

Related Links:
Ecole Polytechnique Fédérale de Lausanne


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.